Arbutus Retained Earnings from 2010 to 2025

ABUS Stock

USD 3.37 0.02 0.59%

Arbutus Biopharma Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Arbutus Biopharma Corp retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2000-03-31

Previous Quarter

-1.3 B

Current Value

-1.3 B

Quarterly Volatility

441.2 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 701.5 K or Selling General Administrative of 27.1 M, as well as many indicators such as Price To Sales Ratio of 13.01, Dividend Yield of 0.0529 or PTB Ratio of 8.02. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.

Check out the analysis of Arbutus Biopharma Correlation against competitors.

Latest Arbutus Biopharma's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Arbutus Biopharma Corp over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Arbutus Biopharma's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (1.28 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Arbutus Retained Earnings Regression Statistics

	Arithmetic Mean	(700,625,732)
	Geometric Mean	485,257,923
	Coefficient Of Variation	(63.13)
	Mean Deviation	388,629,959
	Median	(738,070,000)
	Standard Deviation	442,329,686
	Sample Variance	195655.6T
	Range	1.3B
	R-Value	(0.95)
	Mean Square Error	20772.2T
	R-Squared	0.90
	Slope	(88,184,682)
	Total Sum of Squares	2934833.3T

Arbutus Retained Earnings History

	2025	-1.1 B
	2024	-1.1 B
	2023	-1.3 B
	2022	-1.2 B
	2021	-1.1 B
	2020	-1 B
	2019	-970.1 M

Other Fundumenentals of Arbutus Biopharma Corp

Retained Earnings Total Equity

Arbutus Biopharma Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Accumulated Depreciation	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.72	-0.04	-0.09	0.1	0.97	0.72	-0.22	0.64	0.9	0.37	0.06	0.96	0.21	0.42	0.97	0.19	-0.15	0.02	-0.05	0.08	0.14	0.08	-0.05
Total Stockholder Equity	1.0		-0.74	-0.03	-0.09	0.08	0.95	0.72	-0.23	0.62	0.9	0.37	0.05	0.95	0.23	0.42	0.96	0.21	-0.17	0.0	-0.07	0.09	0.15	0.11	-0.07
Net Debt	-0.72	-0.74		-0.2	-0.06	0.38	-0.64	-0.52	0.24	-0.41	-0.64	0.02	0.29	-0.7	-0.33	-0.25	-0.68	0.15	0.23	0.19	0.25	-0.25	-0.19	-0.25	0.19
Retained Earnings	-0.04	-0.03	-0.2		-0.06	-0.83	-0.07	-0.56	0.09	0.29	-0.01	-0.78	-0.91	0.12	-0.38	-0.63	0.04	-0.57	-0.75	-0.95	-0.36	0.34	0.39	-0.22	-0.76
Net Receivables	-0.09	-0.09	-0.06	-0.06		-0.03	-0.07	0.02	0.04	-0.21	-0.08	-0.12	-0.17	-0.06	-0.02	-0.2	-0.07	-0.31	0.3	0.12	0.23	-0.13	-0.05	-0.03	0.23
Short Term Investments	0.1	0.08	0.38	-0.83	-0.03		0.15	0.53	-0.2	-0.08	0.13	0.81	0.86	-0.06	0.24	0.68	0.0	0.56	0.68	0.76	0.47	-0.48	-0.24	0.13	0.64
Total Liab	0.97	0.95	-0.64	-0.07	-0.07	0.15		0.7	-0.17	0.66	0.89	0.38	0.07	0.96	0.13	0.42	0.96	0.15	-0.09	0.05	-0.02	0.06	0.11	-0.01	0.0
Total Current Assets	0.72	0.72	-0.52	-0.56	0.02	0.53	0.7		-0.38	0.34	0.63	0.76	0.53	0.54	0.5	0.78	0.58	0.45	0.32	0.56	0.12	0.04	-0.03	0.26	0.39
Common Stock	-0.22	-0.23	0.24	0.09	0.04	-0.2	-0.17	-0.38		-0.25	-0.15	-0.22	-0.18	-0.13	-0.12	-0.41	-0.13	-0.16	-0.03	-0.11	0.0	0.0	0.1	0.01	-0.03
Short Term Debt	0.64	0.62	-0.41	0.29	-0.21	-0.08	0.66	0.34	-0.25		0.58	-0.1	-0.1	0.61	-0.23	0.15	0.6	0.17	-0.51	-0.38	-0.22	0.22	0.33	-0.08	-0.41
Net Tangible Assets	0.9	0.9	-0.64	-0.01	-0.08	0.13	0.89	0.63	-0.15	0.58		0.33	-0.04	0.88	0.26	0.39	0.87	-0.04	0.01	0.02	0.13	-0.13	0.44	0.29	0.13
Accounts Payable	0.37	0.37	0.02	-0.78	-0.12	0.81	0.38	0.76	-0.22	-0.1	0.33		0.76	0.22	0.47	0.67	0.28	0.49	0.54	0.81	0.33	-0.17	-0.2	0.27	0.65
Long Term Debt	0.06	0.05	0.29	-0.91	-0.17	0.86	0.07	0.53	-0.18	-0.1	-0.04	0.76		-0.13	0.27	0.63	-0.05	0.8	0.5	0.8	0.23	-0.23	-0.43	0.13	0.52
Deferred Long Term Liab	0.96	0.95	-0.7	0.12	-0.06	-0.06	0.96	0.54	-0.13	0.61	0.88	0.22	-0.13		0.03	0.27	0.99	0.0	-0.25	-0.13	-0.06	0.07	0.11	-0.03	-0.13
Long Term Investments	0.21	0.23	-0.33	-0.38	-0.02	0.24	0.13	0.5	-0.12	-0.23	0.26	0.47	0.27	0.03		0.34	0.05	0.06	0.48	0.41	-0.07	0.09	0.27	0.54	0.37
Short Long Term Debt	0.42	0.42	-0.25	-0.63	-0.2	0.68	0.42	0.78	-0.41	0.15	0.39	0.67	0.63	0.27	0.34		0.3	0.48	0.46	0.56	0.3	-0.31	-0.26	0.13	0.42
Intangible Assets	0.97	0.96	-0.68	0.04	-0.07	0.0	0.96	0.58	-0.13	0.6	0.87	0.28	-0.05	0.99	0.05	0.3		0.08	-0.21	-0.04	-0.04	0.06	0.07	-0.02	-0.08
Property Plant Equipment	0.19	0.21	0.15	-0.57	-0.31	0.56	0.15	0.45	-0.16	0.17	-0.04	0.49	0.8	0.0	0.06	0.48	0.08		0.05	0.44	0.01	0.04	-0.4	-0.09	0.06
Current Deferred Revenue	-0.15	-0.17	0.23	-0.75	0.3	0.68	-0.09	0.32	-0.03	-0.51	0.01	0.54	0.5	-0.25	0.48	0.46	-0.21	0.05		0.8	0.55	-0.56	-0.1	0.29	0.88
Capital Surpluse	0.02	0.0	0.19	-0.95	0.12	0.76	0.05	0.56	-0.11	-0.38	0.02	0.81	0.8	-0.13	0.41	0.56	-0.04	0.44	0.8		0.49	-0.31	-0.31	0.25	0.88
Accumulated Depreciation	-0.05	-0.07	0.25	-0.36	0.23	0.47	-0.02	0.12	0.0	-0.22	0.13	0.33	0.23	-0.06	-0.07	0.3	-0.04	0.01	0.55	0.49		-0.8	0.0	0.29	0.71
Long Term Debt Total	0.08	0.09	-0.25	0.34	-0.13	-0.48	0.06	0.04	0.0	0.22	-0.13	-0.17	-0.23	0.07	0.09	-0.31	0.06	0.04	-0.56	-0.31	-0.8		0.07	-0.31	-0.55
Net Invested Capital	0.14	0.15	-0.19	0.39	-0.05	-0.24	0.11	-0.03	0.1	0.33	0.44	-0.2	-0.43	0.11	0.27	-0.26	0.07	-0.4	-0.1	-0.31	0.0	0.07		0.49	-0.01
Net Working Capital	0.08	0.11	-0.25	-0.22	-0.03	0.13	-0.01	0.26	0.01	-0.08	0.29	0.27	0.13	-0.03	0.54	0.13	-0.02	-0.09	0.29	0.25	0.29	-0.31	0.49		0.44
Capital Stock	-0.05	-0.07	0.19	-0.76	0.23	0.64	0.0	0.39	-0.03	-0.41	0.13	0.65	0.52	-0.13	0.37	0.42	-0.08	0.06	0.88	0.88	0.71	-0.55	-0.01	0.44

Click cells to compare fundamentals

About Arbutus Biopharma Financial Statements

Arbutus Biopharma shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-1.1 B	-1.1 B
Retained Earnings Total Equity	-1.1 B	-1 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC